Celldex Therapeutics Reported Data Showing Barzolvolimab Improves Angioedema At 12 Weeks In Phase 2 Study For Chronic Spontaneous Urticaria
Portfolio Pulse from Charles Gross
Celldex Therapeutics (NASDAQ:CLDX) announced positive Phase 2 trial results for barzolvolimab, showing significant improvement in angioedema symptoms in patients with chronic spontaneous urticaria (CSU) after 12 weeks.
June 02, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics reported that its drug barzolvolimab significantly improves angioedema symptoms in chronic spontaneous urticaria patients after 12 weeks in a Phase 2 trial.
The positive Phase 2 trial results for barzolvolimab indicate potential efficacy in treating a debilitating symptom of CSU, which could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100